FDA notifications. FDA revises Baraclude labeling for HIV patients.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D024882:Drug Resistance, Viral; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; C413685:entecavir; D006147:Guanine